Syntaxin's Acquisition

Syntaxin was acquired by Ipsen on July 15, 2013.

Syntaxin discovers and develops a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSIs) that treat disease through selective inhibition of cell secretory pathways. It is developing TSI…

Articles about Syntaxin's Acquisition: